PLEX®

# Human PD-L1 (epitope 1)

#### www.mesoscale

www.mesoscale.com®	Product Options	Catalog Number	Description	
	Multiplex	K151AEM, K251AEM	U-PLEX Immuno-Oncology Group 1 (human)	
Ordering Information MSD Customer Service Phone: 1-240-314-2795 Fax: 1-301-990-2776 Email: CustomerService@ mesoscale.com	Singleplex	K151Z7K-1/-2/-4	U-PLEX Human PD-L1 (epitope 1) Assay with SECTOR <sup>™</sup> plates	
		K151Z7K-21/-22/-24	U-PLEX Human PD-L1 (epitope 1) Assay with QuickPlex® plates	
		K251Z7K-2/-4	U-PLEX Human PD-L1 (epitope 1) Assay with 384-well plates	
	Antibody Set	B22Z7-2/-3	U-PLEX Human PD-L1 (epitope 1) Antibody Set	
	Protocol	U-PLEX Product Inserts are available at <u>www.mesoscale.com</u>		

The U-PLEX® platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet

provides the representative performance of the U-PLEX Human PD-L1 (epitope 1) Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex.

The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative

data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for


Scientific Support Phone: 1-240-314-2798 Email: ScientificSupport@ mesoscale.com

#### **Company Address**

MESO SCALE DISCOVERY® A division of Meso Scale Diagnostics, LLC. 1601 Research Boulevard Rockville, MD 20850-3173 USA

### Representative Calibration Curve and Sensitivity

instrument compatibility.



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)	
PD-L1 (epitope)	0.09	0.04-0.34	

The Calibrator curve was fitted with a 4-parameter logistic model with a 1/Y<sup>2</sup> weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

#### Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	182	3.5	7.2
Mid	35	3.2	12.5
Low	6.6	6.7	22.5

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

Note: PD-L1 (epitope 1) is significantly impacted by Atezolizumab (Tecentrig). PD-L1 (epitope 2) is not significantly affected by this therapeutic antibody.

For Research Use Only. Not for use in diagnostic procedures.





## MSD® U-PLEX Human PD-L1 (epitope 1)

#### Tested Samples

Sample Type	Serum (N=10)	EDTA Plasma (N=10)	Normal Lysate (N=5)	Tumor Lysate (N=5)
Median (pg/mL)	111	123	67	1,030
Range (pg/mL)	80-292	89-176	1.1-997	27-2,030
% Detected	100	100	100	100

Normal serum and plasma samples were diluted 4-fold prior to the assay. Lysates were tested at a protein concentration of 0.5 mg/mL.

#### **Dilution Linearity**

Serum			EDTA Plasma		
Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution Average % Recovery		% Recovery Range
2	91	87 - 97	2	88	79 - 94
8	99	97 - 102	8	98	93 - 101
16	97	92 - 102	16	98	96 - 102

Normal human serum and EDTA plasma were spiked with Calibrator and tested at different dilutions. Percent recovery at each dilution level was normalized to the dilutionadjusted, 4-fold concentration. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

#### Spike Recovery

	Ser	um	EDTA Plasma	
Spike Level	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	104	100 - 109	101	96 - 108
Mid	99	77 - 110	105	101 - 108
Low	110	100 - 132	104	98 - 109

Normal serum and plasma were spiked with Calibrator at 3 levels. Spiked samples were diluted 4-fold to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

#### Specificity

To assess specificity, the PD-L1 (epitope 1) Antibody Set was tested individually against a larger panel of analytes for nonspecific binding: APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD276/B7-H3, CD28, CD40L (soluble), CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, G-CSF, Galectin-9, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO- $\alpha$ , HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOSL/B7-H2, IFN- $\alpha$ 2a, IFN- $\beta$ , IFN- $\gamma$ , IL-1 $\alpha$ , IL-1 $\beta$ , IL-1RA, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL 25, IL-17F, IL-18, IL-2, IL-22, IL-23, IL-27, IL-29/IFN- $\lambda$ 1, IL-2R $\alpha$ , IL-3, IL-31, IL-33, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, I-TAC, LAG-3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1 $\alpha$ , MIP-5, MMP-1, MMP-2, MMP-7, MMP-9, Nectin-4, OX40/TNFRSF4, PD1, PD-L1, PD-L2, Pentraxin 3, Perforin, PIGF, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, SDF-1 $\alpha$ , TARC, Tie-2, TIGIT, TLR-1, TNF-RI, TNF-RII, TNF- $\alpha$ , TNF- $\beta$ , TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/FIt-1 and YKL-40. Nonspecific binding was less than 2.0%.

#### % Nonspecificity = (nonspecific signal / specific signal) x 100

The PD-L1 (epitope 1) assay will cross-react with the PD-L1 (epitope 2). We do not recommend multiplexing the PD-L1 (epitope 1) assay with the PD-L1 (epitope 2) assay.

#### **Diluent Compatibility**

Diluents 58 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

#### Assay Components

**Calibrator:** PD-L1 (epitope 1) is included in Calibrator 21. The human PD-L1 (epitope 1) Calibrator is PD-L1 (19–239) expressed in a human cell line. **Antibodies:** The U-PLEX Human PD-L1 (epitope 1) Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection. **Assay generation:** A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.

MESO SCALE DISCOVERY, Meso Scale Diagnostics, www.mesoscale.com, MSD, MSD (design), QuickPlex, SECTOR, U-PLEX, U-PLEX (design), 96 WELL SMALL-SPOT (design), and Spot the Difference are trademarks and/or service marks of Meso Scale Diagnostics, LLC. ©2016-2023 Meso Scale Diagnostics, LLC. All rights reserved.

